Tumor Biology

, Volume 36, Issue 2, pp 959–966 | Cite as

The high-mobility group nucleosome-binding domain 5 is highly expressed in breast cancer and promotes the proliferation and invasion of breast cancer cells

  • Mingzhe Weng
  • Fangbin Song
  • Jinyu Chen
  • Junyi Wu
  • Jun Qin
  • Tao Jin
  • Junming Xu
Research Article


The high-mobility group nucleosome-binding domain 5 (HMGN5) is a member of the high-mobility group proteins family. Previous study found that HMGN5 is required for tumorigenesis in vitro, and aberrations in the expression of HMGN5 were found in human osteosarcoma, prostate cancer, and squamous cell carcinoma. Nevertheless, the role of HMGN5 in breast cancer remains unclear. This study aimed to investigate the expression and clinical significance of HMGN5 in human breast cancer, confirm the oncogenic role of HMGN5, and explore the mechanism by which HMGN5 contributes to invasion and metastasis. HMGN5 expression was detected in breast cancer tissues and corresponding adjacent non-cancerous tissues from 43 patients by immunohistochemistry, and the clinicopathologic characteristics of all patients were also analyzed. Next, knockdown of HMGN5 protein in MDA-MB-231 cells was performed through a small interfering RNA (siRNA) technique, and cell viability, apoptosis, and invasion were detected by cell vitality test, flow cytometry, and transwell assay, respectively. Immunohistostaining showed that HMGN5 were highly expressed in the nucleus in all breast cancer tissues as compared with the adjacent non-cancerous tissues (ANCT;(73.5 ± 11 vs. 31.0 ± 5 %, P < 0.01). HMGN5 expression level was associated with the poorly differentiated tumor cells, lymph node involvement tumor, and T4 staging tumor. Knockdown of HMGN5 inhibited cell growth, suppressed invasion, and increased cell apoptosis in human breast cancer MDA-MB-231 cells. Western blot analysis demonstrated that the expressions of PCNA, connective tissue growth factor (CTGF), and MMP-9 were decreased in human breast MDA-MB-231 cells depleted of HMGN5. In addition, the apoptotic markers (cleaved PARP and cleaved caspase-3) were significantly increased by HMGN5 knockdown, but microtubule-associated protein 1 light chain 3-II/I (LC3-II/I) did not alter. HMGN5 plays an oncogenic role in human breast cancer by inhibiting cell proliferation and invasion, and activating apoptosis, which could be exploited as a target for therapy in human breast cancer.


High-mobility group nucleosome-binding domain 5 Breast cancer Proliferation Invasion Apoptosis Autophagy 



This work is supported by the scientific research project of Shanghai Science and Technology Committee (14411950205, 14411950200).

Conflicts of interest



  1. 1.
    Chen LC, Tu SH, Huang CS, Chen CS, Ho CT, Lin HW, et al. Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway. Breast Cancer Res Treat. 2012;134:989–1004.CrossRefPubMedGoogle Scholar
  2. 2.
    Caplan L. Delay in breast cancer: implications for stage at diagnosis and survival. Front Publ Health. 2014;2:87.CrossRefGoogle Scholar
  3. 3.
    Gill M, McCarthy M, Murrells T, Silcocks P. Chemotherapy for the primary treatment of osteosarcoma: population effectiveness over 20 years. Lancet. 1988;1:689–92.CrossRefPubMedGoogle Scholar
  4. 4.
    Bustin M, Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol. 1996;54:35–100.CrossRefPubMedGoogle Scholar
  5. 5.
    Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 1999;19:5237–46.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Rattner BP, Yusufzai T, Kadonaga JT. HMGN proteins act in opposition to ATP-dependent chromatin remodeling factors to restrict nucleosome mobility. Mol Cell. 2009;34:620–6.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Birger Y, West KL, Postnikov YV, Lim JH, Furusawa T, Wagner JP, et al. Chromosomal protein hmgn1 enhances the rate of DNA repair in chromatin. EMBO J. 2003;22:1665–75.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Birger Y, Catez F, Furusawa T, Lim JH, Prymakowska-Bosak M, West KL, et al. Increased tumorigenicity and sensitivity to ionizing radiation upon loss of chromosomal protein hmgn1. Cancer Res. 2005;65:6711–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Zhou X, Yuan B, Yuan W, Wang C, Gao R, Wang J. The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma. Tumour Biol. 2014;35:6539–47.CrossRefPubMedGoogle Scholar
  10. 10.
    Huang C, Zhou LQ, Song G. Effect of nucleosomal binding protein 1 in androgen-independent prostatic carcinoma. Zhonghua Yi Xue Za Zhi. 2008;88:657–60.PubMedGoogle Scholar
  11. 11.
    Green J, Ikram M, Vyas J, Patel N, Proby CM, Ghali L, et al. Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. Br J Cancer. 2006;94:1446–51.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Tang WY, Newbold R, Mardilovich K, Jefferson W, Cheng RY, Medvedovic M, et al. Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology. 2008;149:5922–31.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wahafu W, He ZS, Zhang XY, Zhang CJ, Yao K, Hao H, et al. The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells. Tumour Biol. 2011;32:931–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Ji SQ, Yao L, Zhang XY, Li XS, Zhou LQ. Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cell carcinoma cells in vitro and in vivo. J Exp Clin Cancer Res. 2012;31:22.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rochman M, Malicet C, Bustin M. Hmgn5/nsbp1: a new member of the hmgn protein family that affects chromatin structure and function. Biochim Biophys Acta. 2010;1799:86–92.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Wang L, Zhang H, Qian J, Wang K, Zhu J. Interleukin-10 blocks in vitro replication of human cytomegalovirus by inhibiting the virus-induced autophagy in MRC5 cells. Biochem Biophys Res Commun. 2014;448:448–53.CrossRefPubMedGoogle Scholar
  17. 17.
    Yang C, Gao R, Wang J, Yuan W, Wang C, Zhou X. High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy. Tumour Biol. 2014;35:6357–63.CrossRefPubMedGoogle Scholar
  18. 18.
    Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Ye L, Bokobza S, Li J, Moazzam M, Chen J, Mansel RE, et al. Bone morphogenetic protein-10 (BMP-10) inhibits aggressiveness of breast cancer cells and correlates with poor prognosis in breast cancer. Cancer Sci. 2010;101:2137–44.CrossRefPubMedGoogle Scholar
  20. 20.
    Jang SY, Kim A, Kim JK, Kim C, Cho YH, Kim JH, et al. Metformin inhibits tumor cell migration via down-regulation of MMP9 in tamoxifen-resistant breast cancer cells. Anticancer Res. 2014;34:4127–34.PubMedGoogle Scholar
  21. 21.
    Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol. 2007;8:741–52.CrossRefPubMedGoogle Scholar
  22. 22.
    Thorburn A. Apoptosis and autophagy: regulatory connections between two supposedly different processes. Apoptosis. 2008;13:1–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Hock R, Furusawa T, Ueda T, Bustin M. Hmg chromosomal proteins in development and disease. Trends Cell Biol. 2007;17:72–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Qu J, Yan R, Chen J, Xu T, Zhou J, Wang M, et al. HMGN5: a potential oncogene in gliomas. J Neurooncol. 2011;104:729–36.CrossRefPubMedGoogle Scholar
  25. 25.
    Li DQ, Hou YF, Wu J, Chen Y, Lu JS, Di GH, et al. Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. Eur J Cancer. 2006;42:3274–86.CrossRefPubMedGoogle Scholar
  26. 26.
    Pritsker M, Ford NR, Jenq HT, Lemischka IR. Genomewide gain-of-function genetic screen identifies functionally active genes in mouse embryonic stem cells. Proc Natl Acad Sci U S A. 2006;103:6946–51.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, et al. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol. 2013;34:81–90.CrossRefPubMedGoogle Scholar
  28. 28.
    Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, et al. Hmgb1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 2003;17:1295–7.PubMedGoogle Scholar
  29. 29.
    He Q, Liang CH, Lippard SJ. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A. 2000;97:5768–72.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Casimiro S, Luis I, Fernandes A, Pires R, Pinto A, Gouveia AG, et al. Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. Clin Exp Metastasis. 2012;29:155–64.CrossRefPubMedGoogle Scholar
  31. 31.
    Liao XH, Lu DL, Wang N, Liu LY, Wang Y, Li YQ, et al. Estrogen receptor alpha mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway. FEBS J. 2014;281:927–42.CrossRefPubMedGoogle Scholar
  32. 32.
    Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, et al. Is Ki-67 expression prognostic for local relapse in early-stage breast cancer patients treated with breast conservation therapy (BCT)? Int J Radiat Oncol Biol Phys. 2013;87:344–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Fan SH, Wang YY, Lu J, Zheng YL, Wu DM, Zhang ZF, et al. CERS2 suppresses tumor cell invasion and is associated with decreased v-ATPase and MMP-2/MMP-9 activities in breast cancer. J Cell Biochem. 2014, in press.Google Scholar
  34. 34.
    Li L, Wang Y, Qi B, Yuan D, Dong S, Guo D, Zhang C, Yu M. Suppression of PMA-induced tumor cell invasion and migration by ginsenoside Rg1 via the inhibition of NF-κB-dependent MMP-9 expression. Oncol Rep. 2014, in press.Google Scholar
  35. 35.
    Zhou R, Xu L, Ye M, Liao M, Du H, Chen H. Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm Metab Res. 2014, in press.Google Scholar
  36. 36.
    Tong J, Yin S, Dong Y, Guo X, Fan L, Ye M, et al. Pseudolaric acid b induces caspase-dependent apoptosis and autophagic cell death in prostate cancer cells. Phytother Res. 2013;27:885–91.CrossRefPubMedGoogle Scholar
  37. 37.
    Ren SX, Shen J, Cheng AS, Lu L, Chan RL, Li ZJ, et al. FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One. 2013;8:e63641.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Yang YH, Li B, Zheng XF, Cheng JW, Chen K, Jiang SD, et al. Oxidative damage to osteoblasts can be alleviated by early autophagy through the endoplasmic reticulum stress pathway-implications for the treatment of osteoporosis. Free Radic Biol Med. 2014, in pressGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Mingzhe Weng
    • 1
  • Fangbin Song
    • 1
  • Jinyu Chen
    • 2
  • Junyi Wu
    • 1
  • Jun Qin
    • 1
  • Tao Jin
    • 1
  • Junming Xu
    • 1
  1. 1.Department of General Surgery of Shanghai First People’s HospitalShanghai Jiaotong UniversityShanghaiChina
  2. 2.Department of Endocrinology, Shanghai First People’s HospitalShanghai Jiaotong UniversityShanghaiChina

Personalised recommendations